Search results for "Farmaceutica"

showing 10 items of 582 documents

Le piante medicinali nell'Acis Hortus Regius del farmacista Giuseppe Riggio (1758-1830)

2009

Botanica farmaceutica SiciliaSettore BIO/15 - Biologia Farmaceutica
researchProduct

Pharmaceutical patents and the right to access to medicines in Central America

2020

El vínculo entre la propiedad intelectual y el derecho a la salud se ha convertido en un tema de debate central desde la conferencia ministerial de la Organización Mundial del Comercio (OMC) en 2001. En efecto, a pesar del amplio reconocimiento del derecho a la salud en la escena internacional, la cuestión de la protección efectiva y la aplicación del derecho en cuestión es tema de un debate constante. El objetivo de las patentes farmacéuticas, es proporcionar al inventor un conjunto de derechos exclusivos durante un período de tiempo determinado a cambio de la divulgación pública del medicamento recién protegido. El régimen de monopolio establecido conduce a un aumento significativo de los…

CAFTATRIPSpharmaceutical patentright to healthacceso a medicamentos:CIENCIAS JURÍDICAS Y DERECHO [UNESCO]Settore IUS/13 - Diritto InternazionaleUNESCO::CIENCIAS JURÍDICAS Y DERECHOpatentes farmaceuticasderechos humanosderecho a la saludaccess to medicines
researchProduct

Novel 1H‑Pyrrolo[2,3‑b]pyridine Derivative Nortopsentin Analogues: Synthesis and Antitumor Activity in Peritoneal Mesothelioma Experimental Models

2013

In this study, we describe the synthesis of new nortopsentin analogues, 1H-pyrrolo[2,3-b]pyridine derivatives and their biological effects in experimental models of diffuse malignant peritoneal mesothelioma (DMPM), a rare and rapidly fatal disease, poorly responsive to conventional therapies. The three most active compounds, 1f (3-[2-(5-fluoro-1-methyl-1H-indol-3- yl)-1,3-thiazol-4-yl]-1H-pyrrolo[2,3-b]pyridine), 3f (3-[2-(1H-indol-3-yl)-1,3- thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-b]pyridine), and 1l (3-[2-(5-fluoro-1- methyl-1H-indol-3-yl)-1,3-thiazol-4-yl]-1-methyl-1H-pyrrolo[2,3-b] pyridine), which were shown to act as cyclin-dependent kinase 1 inhibitors, consistently reduced DMPM cell p…

CDK1 inhibitorsmalignant peritoneal mesothelioma3‑b]pyridineNortopsentin Analogues1H‑Pyrrolo[21H‑Pyrrolo[23‑b]pyridineCDK1 inhibitorsNortopsentin AnalogueSettore CHIM/08 - Chimica Farmaceuticamalignant peritoneal mesothelioma; 1H‑Pyrrolo[2; 3‑b]pyridine; Nortopsentin Analogues; CDK1 inhibitors
researchProduct

SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL SMALL MOLECULES AS PROMISING ALTERNATIVE AGENTS TO COUNTERACT DRUG RESISTANCE IN CANCER AND MICROBIAL IN…

2022

Il cancro rimane un grave problema di salute pubblica, rappresentando la seconda principale causa di morte in tutto il mondo. Tra le diverse tipologie di tumori, l'adenocarcinoma duttale pancreatico (PDAC) è una delle forme più letali nell'uomo, a causa della diagnosi tardiva e delle limitate possibilità di trattamento. Pertanto, lo studio di nuove strategie terapeutiche per i pazienti affetti da PDAC è altamente necessario. Allo stesso modo, il mesotelioma rappresenta una malattia rara ma aggressiva, difficile da diagnosticare per il lungo periodo di latenza prima dei segni clinici. Gli approcci terapeutici standard includono la chirurgia, la chemioterapia e la radioterapia. Tuttavia, la s…

CDK1Antibiofilm activityGSK3βMesothelioma ImidazothiadiazolePancreatic cancer124-OxadiazoleSettore CHIM/08 - Chimica Farmaceutica
researchProduct

ANALISI CHIMICO-TOSSICOLOGICA E CHEMIOMETRICA DI SEDIMENTI MARINO COSTIERI SICILIANI

2011

CHEMIOMETRICACHIMICO-TOSSICOLOGICASettore CHIM/08 - Chimica Farmaceutica
researchProduct

SYNTHETIC AND BIOLOGICAL EVALUATION OF SOME NEW 2-CINNAMAMIDOBENZAMIDES AS POTENTIAL ANTAGONIST OF THE HDM2-P53 PROTEIN-PROTEIN INTERACTIONS

2008

CINNAMAMMIDOBENZAMIDES ANTIPROLIFERATIVE ACTIVITYSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Studio del ruolo delle mutazioni “gatekeeper” V654A e T670I di c-kit kinase nell’interazione con inibitori attraverso un approccio misto Dinamica Mol…

2012

La sovraespressione del proto-oncogene c-kit è stata riscontrata nelle cellule ematopoietiche, nel cancro a piccole cellule del polmone e nei tumori stromali gastrointestinali1-3. L’importanza clinica dell’espressione di c-kit nei tumori ha indirizzato la ricerca verso inibitori di questa tirosina chinasi. Imatinib (Gleevec®) (in figura) è stato il primo farmaco utilizzato in terapia, ma la comparsa di mutazioni su c-kit ha portato ad una riduzione dell’efficacia o a completa resistenza a questo trattamento. In alternativa, altri composti si sono mostrati attivi anche nei confronti dei mutanti come ad esempio Sunitinib (Sutent®)4, ma la necessità di nuovi e più efficaci inibitori contro i m…

CKIT MUTAZIONI INDUCED-FIT DOCKINGSettore CHIM/08 - Chimica Farmaceutica
researchProduct

4,5,6,9-TETRAHYDROPYRROLO[2',3'-3,4]CYCLOEPTA[1,2-d]ISOSSAZOLE, PROCESS FOR THEIR PRODUCTION AND THEIR USES AS ANTITUMOR AGENTS

2016

The present invention concerns the synthesis of compounds bearing the PYRROLO[2',3'-3,4]CYCLOEPTA[1,2-d]ISOSSAZOLE structure, and their use for the treatment of pathologies having hyperproliferative features included those having neoplastic nature.

CYCLOEPTAISOSSAZOLE ANTITUMOR AGENTSSettore CHIM/08 - Chimica Farmaceutica
researchProduct

Hand-made paper obtained by green procedure of cladode waste of Opuntia ficus indica (L.) Mill. from Sicily

2019

Cellulosic fibres have been obtained by green procedures from the cladodes of Opuntia ficus indica (L.) Mill., constituting a large agro industrial waste in our territory. The materials have been analysed for its relative composition, applying, IR and TG methodologies and it was characterised by the absence of lignin. The fibrous material allowed the manufacture of a handmade paper obtaining an ecological material suitable for packaging purposes. The authors evidenced that the simple protocol based on hot water treatment was able to decrease the amount of hemicellulose in the final material.

CactaceaeOpuntia ficusPlant Science01 natural sciencesBiochemistryIndustrial wasteAnalytical Chemistrychemistry.chemical_compoundSettore ICAR/13 - Disegno IndustrialeCladodesLigninHemicelluloseSettore BIO/15 - Biologia FarmaceuticaCelluloseOpuntia ficus indicaSettore CHIM/02 - Chimica Fisicabiology010405 organic chemistrypaperOrganic ChemistrySettore CHIM/06 - Chimica Organicabiology.organism_classificationPulp and paper industrycellulose0104 chemical sciencesSettore AGR/03 - Arboricoltura Generale E Coltivazioni Arboree010404 medicinal & biomolecular chemistrychemistryCellulosic ethanolEnvironmental science
researchProduct

The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistan…

2013

The identification of novel compounds modulating the expression/activity of molecular targets downstream to BCR-ABL could be a new approach in the treatment of chronic myeloid leukemias (CMLs) resistant to imatinib or other BCR-ABL-targeted molecules. Recently, we synthesized a new class of substituted 2-(3,4,5-trimethoxybenzoyl)-2-N,N-dimethylamino-benzo[b]furans, and among these 3-iodoacetylamino-6-methoxybenzofuran-2-yl(3,5-trimethoxyphenyl)methanone (TR120) showed marked cytotoxic activity in BCR-ABL-expressing cells. Interestingly, TR120 was more potent than imatinib in cell growth inhibition and apoptosis induction in both BCR-ABL-expressing K562 and KCL22 cells. Moreover, it showed a…

Cancer ResearchFusion Proteins bcr-ablApoptosisPiperazinesSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundhemic and lymphatic diseasesSTAT5 Transcription FactorCytotoxic T cellPharmacology (medical)Cyclin D1STAT5biologyDrug SynergismCell cycleNeoplasm ProteinsGene Expression Regulation NeoplasticLeukemiaOncologyProto-Oncogene Proteins c-bcl-2BenzamidesImatinib MesylateGrowth inhibitionmedicine.drugbcl-X ProteinDown-RegulationAntineoplastic AgentsBone Marrow CellsResting Phase Cell CycleColony-Forming Units AssayBenzophenonesNecrosisCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositivemedicineHumansneoplasmsBenzofuransPharmacologyG1 PhaseImatinibBCR-ABL chronic myeloid leukemia imatinib resistance STAT5 tyrosine kinase inhibitorsmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaGenes bcl-1Genes bcl-2PyrimidineschemistryApoptosisDrug Resistance NeoplasmSettore BIO/14 - FarmacologiaCancer researchbiology.proteinK562 CellsK562 cells
researchProduct